GSK consensus picture stays clear, analysts see modest upside for the shares
29.06.2026 - 14:46:42 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 14:46.
GSK plc (GB0009252882) starts the new week with a consistent analyst stance around its London listing. The shares last closed at 1,983 pence on the London Stock Exchange, with the average target price sitting moderately higher according to MarketScreener data.MarketScreener consensus overview
What analysts expect today
MarketScreener shows GSK with a last close at 1,983 pence, while the average analyst target price is 2,087 pence, implying roughly 5 percent upside from the latest quote.MarketScreener consensus data The site also notes a year-to-date share price gain of 8.69 percent, signaling a relatively robust performance versus the start of 2026.MarketScreener performance metrics
In late June, Bernstein highlighted GSK as "poised for sustainable growth" with a "much more durable" HIV franchise, and lifted its price target, pointing to ongoing confidence in the company’s longer-term earnings profile.Bernstein note summary on MarketScreener This research call adds to the broader positive tilt in the analyst community, even if the expected upside remains measured.
How the stock has performed
The MarketScreener snapshot indicates that GSK shares are up nearly 3 percent over the last five trading days and almost 9 percent since the beginning of the year, a move that compares relatively well with many large-cap European pharma names.MarketScreener five-day and YTD data In sterling terms, the stock trades just below the blended analyst target, reflecting that part of the forecasted rerating has already been realized.
German investors also follow GSK via secondary quotes, where the shares recently traded around 23 euros on Stuttgart Exchange, an indication of the parallel euro-denominated pricing for the London-listed equity.Finanzen.net GSK quote and analysis page This cross-venue presence underlines the stock’s relevance for both UK and continental European portfolios.
Background and price data on GSK
For more news, regulatory filings and detailed price information on the GSK shares, the following overviews provide a broader context.
The products behind the stock
GSK generates revenue largely through vaccines, specialty medicines and general medicines, with a focus on infectious diseases, HIV and respiratory conditions.GSK investor overview A key example is the shingles vaccine Shingrix, which has become one of the company’s leading growth drivers in recent years and features prominently in its portfolio disclosures.GSK product and portfolio information
Where the shares trade today
The GSK shares (GB0009252882) last closed on the London Stock Exchange on 2026-06-26 at 19.83 pounds sterling, based on MarketScreener’s consolidated quote data.MarketScreener GSK quote page
Key data on the GSK shares
- Company: GSK plc
- ISIN: GB0009252882
- WKN: 940130
- Ticker: GSK
- Trading venue: London Stock Exchange
- Price (as of 2026-06-26, 16:35): 19.83 GBP
- Market cap: approximately 80 billion GBP (as of 2026-06-26)
- Sector / industry: Pharmaceuticals & biotechnology
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any transaction. All data cited are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
